Bank of America
NAVB

Bank of America’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bank of America’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,604
Closed -$143 – 8436
2023
Q3 		$143 Hold
1,604
– – ﹤0.01% 7440
2023
Q2 		$148 Buy
1,604
+425
+36% +$68 ﹤0.01% 7400
2023
Q1 		$307 Hold
1,179
– – ﹤0.01% 7400
2022
Q4 		$248 Sell
1,179
-543
-32% -$136 ﹤0.01% 7514
2022
Q3 		$0 Hold
1,722
– – ﹤0.01% 8609
2022
Q2 		$1K Hold
1,722
– – ﹤0.01% 7951
2022
Q1 		$1K Sell
1,722
-193
-10% -$177 ﹤0.01% 8190
2021
Q4 		$2K Buy
1,915
+93
+5% +$131 ﹤0.01% 8028
2021
Q3 		$3K Sell
1,822
-7
-0.4% -$12 ﹤0.01% 7859
2021
Q2 		$3K Buy
1,829
+7
+0.4% +$12 ﹤0.01% 7525
2021
Q1 		$3K Sell
1,822
-625
-26% -$1.46K ﹤0.01% 7216
2020
Q4 		$5K Sell
2,447
-175
-7% -$413 ﹤0.01% 6839
2020
Q3 		$6K Sell
2,622
-1,153
-31% -$4.14K ﹤0.01% 6573
2020
Q2 		$14K Buy
3,775
+1,428
+61% +$2.73K ﹤0.01% 6358
2020
Q1 		$2K Hold
2,347
– – ﹤0.01% 6685
2019
Q4 		$3K Sell
2,347
-581
-20% -$502 ﹤0.01% 6865
2019
Q3 		$2K Buy
2,928
+1,656
+130% +$1.02K ﹤0.01% 7056
2019
Q2 		$1K Sell
1,272
-8
-0.6% -$16 ﹤0.01% 7128
2019
Q1 		$3K Sell
1,280
-1,075
-46% -$3.17K ﹤0.01% 6887
2018
Q4 		$5K Buy
2,355
+625
+36% +$2.58K ﹤0.01% 6783
2018
Q3 		$8K Hold
1,730
– – ﹤0.01% 6739
2018
Q2 		$8K Sell
1,730
-145
-8% -$758 ﹤0.01% 6721
2018
Q1 		$13K Hold
1,875
– – ﹤0.01% 6539
2017
Q4 		$13K Hold
1,875
– – ﹤0.01% 6560
2017
Q3 		$15K Sell
1,875
-271
-13% -$2.3K ﹤0.01% 6403
2017
Q2 		$22K Buy
2,146
+822
+62% +$8.13K ﹤0.01% 6202
2017
Q1 		$15K Buy
1,324
+4
+0.3% +$45 ﹤0.01% 6430
2016
Q4 		$17K Sell
1,320
-9
-0.7% -$143 ﹤0.01% 6411
2016
Q3 		$24K Sell
1,329
-2,715
-67% -$34.3K ﹤0.01% 6064
2016
Q2 		$43K Buy
4,044
+3,753
+1,290% +$73.7K ﹤0.01% 5898
2016
Q1 		$5K Sell
291
-157
-35% -$3.02K ﹤0.01% 6593
2015
Q4 		$12K Buy
448
+98
+28% +$3.4K ﹤0.01% 6628
2015
Q3 		$16K Sell
350
-650
-65% -$24.5K ﹤0.01% 6403
2015
Q2 		$32K Buy
1,000
+773
+341% +$22.5K ﹤0.01% 6159
2015
Q1 		$7K Buy
227
+73
+47% +$2.47K ﹤0.01% 6426
2014
Q4 		$6K Sell
154
-1,795
-92% -$49.4K ﹤0.01% 7242
2014
Q3 		$51K Sell
1,949
-126
-6% -$3.33K ﹤0.01% 6498
2014
Q2 		$61K Buy
2,075
+1,252
+152% +$40.5K ﹤0.01% 6506
2014
Q1 		$30K Sell
823
-37
-4% -$1.4K ﹤0.01% 6717
2013
Q4 		$36K Buy
860
+90
+12% +$3.52K ﹤0.01% 6753
2013
Q3 		$41K Sell
770
-2,901
-79% -$169K ﹤0.01% 6535
2013
Q2 		$196K Buy
+3,671
New +$183K ﹤0.01% 5638

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Bank of America's NAVB Position: Q4 2023 in Review

Bank of America sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 1,604 shares — an estimated $143 sold.

Bank of America first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $196K in Q2 2013. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Bank of America reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Bank of America sold 1,604 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $143.
  • Bank of America first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
  • Bank of America's Navidea Biopharmaceuticals Inc. position peaked at $196K in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.